MDB Capital leads I-O startup Cue Biopharma in $26M raise

Its platform was originally developed in academia via a grant from the NIH.

Two years after being founded, Cambridge, Massachusetts, upstart Cue Biopharma has raised $26 million to help advance its  work using biologics to target T cell receptors to help patients’ immune systems defeat cancer and autoimmune diseases.

The total $26 million of invested private capital was led by MDB Capital Group, with $10 million of initial seed funding followed up by the $16.4 million in extra financing.

The Cue platform was developed in Almo’s laboratory at the Albert Einstein College, funded by investments from the National Institutes of Health.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Cue Biopharma says that from this, it has developed a “highly productive platform for designing biologic drugs that generate tailored immune responses from disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen presenting cells.”

It is using this approach both on its own, as well as, in the new trend, of combos with checkpoint inhibitors. It also hopes its drugs can yield the desired efficacy with a strong safety profile.

“It has become increasingly clear that more effective and less toxic approaches to immune modulation are needed via precise communication with and control of T cells,” said Daniel Passeri, president and CEO of Cue Biopharma, and former head of Curis.

“With the Cue platform, we have demonstrated selectivity for and modulation of disease-relevant T cells. Our lead candidate has proven highly effective in preclinical cancer models and has shown impressive synergy when combined with checkpoint inhibitors. Our approach to modulating the immune system to treat disease could have great clinical benefit for patients, while reducing collateral toxicities often seen with less selective immunotherapies.”

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.